Epizyme Company Profile (NASDAQ:EPZM)

About Epizyme

Epizyme logoEpizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company's segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. It develops small molecule inhibitors of other chromatin modifying proteins, or CMPs. Its lead product candidate, tazemetostat, is a selective inhibitor of the EZH2 HMT. It is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma, or NHL, and one Phase II study in adults and one Phase I study in children with certain genetically-defined solid tumors. It has programs in development, including a Phase I clinical trial of pinometostat, an inhibitor of the DOT1L HMT, for the treatment of children with MLL-r, an acute leukemia with genetic alterations of the MLL gene.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EPZM
  • CUSIP:
Key Metrics:
  • Previous Close: $9.00
  • 50 Day Moving Average: $9.00
  • 200 Day Moving Average: $10.01
  • 52-Week Range: $7.02 - $18.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.60
  • P/E Growth: 0.00
  • Market Cap: $521.60M
  • Outstanding Shares: 57,956,000
  • Beta: 2.14
  • Net Margins: -5,174.49%
  • Return on Equity: -43.05%
  • Return on Assets: -35.64%
  • Current Ratio: 18.35%
  • Quick Ratio: 18.35%
Additional Links:
Companies Related to Epizyme:

Analyst Ratings

Consensus Ratings for Epizyme (NASDAQ:EPZM) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.50 (172.22% upside)

Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
DateFirmActionRatingPrice TargetDetails
10/7/2016Leerink SwannReiterated RatingOutperformView Rating Details
8/9/2016HC WainwrightReiterated RatingBuyView Rating Details
6/23/2016JMP SecuritiesReiterated RatingBuy$28.00View Rating Details
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingOutperform$26.00View Rating Details
5/9/2016WedbushReiterated RatingOutperform$22.00View Rating Details
4/5/2016Citigroup Inc.Initiated CoverageBuy$17.00View Rating Details
12/22/2015SunTrust Banks Inc.Initiated CoverageBuy$21.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Epizyme (NASDAQ:EPZM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2($0.52)($0.49)ViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)ViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)ViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$5.42 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.45 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$5.63 millionViewN/AView Earnings Details
3/12/2015Q414($0.53)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.55)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.50)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.22)$8.48 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Epizyme (NASDAQ:EPZM)
Current Year EPS Consensus Estimate: $-2.20 EPS
Next Year EPS Consensus Estimate: $-2.50 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.63)($0.42)($0.51)
Q2 20164($0.68)($0.45)($0.55)
Q3 20163($0.64)($0.50)($0.57)
Q4 20163($0.73)($0.55)($0.63)
Q1 20171($0.61)($0.61)($0.61)
Q2 20171($0.64)($0.64)($0.64)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.68)($0.68)($0.68)
(Data provided by Zacks Investment Research)


Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Epizyme (NASDAQ:EPZM)
Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 80.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.36View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.15View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.65View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.00View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.68View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.00View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.37View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.46View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.98View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.32View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.00View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.00View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.00View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.00View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.00View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.00View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.00View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.00View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Epizyme (NASDAQ:EPZM)
News IconCapital Fund Management SA Takes Position in Epizyme Inc. (EPZM) - DailyQuint (NASDAQ:EPZM)
dailyquint.com - October 16 at 4:45 PM
News IconBroker Roundup For Epizyme, Inc. (NASDAQ:EPZM) - The De Soto Edge (NASDAQ:EPZM)
www.desotoedge.com - October 16 at 9:29 AM
investornewswire.com logoEpizyme, Inc. (NASDAQ:EPZM) EPS Surprise Reaches 2% - Investor Newswire (NASDAQ:EPZM)
www.investornewswire.com - October 13 at 10:01 PM
News IconEpizyme Inc. (EPZM) Receives “Outperform” Rating from Leerink Swann - DailyQuint (NASDAQ:EPZM)
dailyquint.com - October 13 at 10:01 PM
News IconEpizyme Inc. (EPZM) Given Consensus Rating of “Buy” by Brokerages - DailyQuint (NASDAQ:EPZM)
dailyquint.com - October 12 at 9:47 AM
News IconStock Ballooning in Midday Session: Epizyme, Inc. (NASDAQ:EPZM) - CSZ News (NASDAQ:EPZM)
cincysportszone.com - October 11 at 5:00 PM
News IconInsiders are Curtailing Holdings in Epizyme, Inc. (NASDAQ:EPZM) - CSZ News (NASDAQ:EPZM)
cincysportszone.com - October 11 at 5:00 PM
News IconIs there Upside to Epizyme, Inc. (NASDAQ:EPZM) ? - Recall News (NASDAQ:EPZM)
www.automobile-recalls.net - October 5 at 10:03 AM
News IconEpizyme, Inc. (NASDAQ:EPZM) Updated Analyst Coverage - NewsDen (NASDAQ:EPZM)
newsden.net - September 28 at 9:44 AM
News IconWere Analysts Bullish Epizyme Inc (NASDAQ:EPZM) This Week? - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 24 at 4:38 PM
News IconFirst Week of EPZM May 2017 Options Trading (NASDAQ:EPZM)
www.stockoptionschannel.com - September 22 at 10:27 AM
streetinsider.com logoEpizyme (EPZM), Foundation Medicine Enter Collaboration on Tazemetostat Phase 2 Enrollment - StreetInsider.com (NASDAQ:EPZM)
www.streetinsider.com - September 21 at 8:48 AM
publicnow.com logoEpizyme Establishes Collaboration with Foundation Medicine to Support Tazemetostat Phase 2 Clinical Trial (NASDAQ:EPZM)
www.publicnow.com - September 21 at 8:48 AM
News IconStock to Watch: Epizyme, Inc. (NASDAQ:EPZM), OraSure Technologies, Inc. (NASDAQ:OSUR) - Newburgh Press (NASDAQ:EPZM)
newburghpress.com - September 19 at 3:44 PM
News IconAnalysts Take the Wheel on Epizyme, Inc. (NASDAQ:EPZM) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:EPZM)
friscofastball.com - September 17 at 4:42 PM
4-traders.com logoEpizyme : Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor (NASDAQ:EPZM)
www.4-traders.com - September 16 at 4:46 PM
finance.yahoo.com logoEpizyme Receives Milestone from Glaxo for Lymphoma Drug (NASDAQ:EPZM)
finance.yahoo.com - September 16 at 4:46 PM
nasdaq.com logoThird Epizyme-discovered product candidate advances into clinical development (NASDAQ:EPZM)
www.nasdaq.com - September 15 at 5:15 PM
streetinsider.com logoEpizyme (EPZM) Announces Earning $6M Milestone Related to GSK3326595 Phase 1 - StreetInsider.com (NASDAQ:EPZM)
www.streetinsider.com - September 15 at 5:15 PM
realistinvestor.com logoEpizyme, Inc. (NASDAQ:EPZM) Is Expected To Post EPS Of $-0.66 - RealistInvestor.com (NASDAQ:EPZM)
www.realistinvestor.com - September 14 at 10:02 PM
News IconShares Higher in Current Session: Epizyme, Inc. (NASDAQ:EPZM) - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 12 at 4:42 PM
News IconEpizyme Inc (NASDAQ:EPZM)’s Futility Hurdle Might Spark A Reversal (NASDAQ:EPZM)
streetregister.com - September 10 at 9:26 AM
News IconStock Showing Gains in Today's Session: Epizyme, Inc. (NASDAQ:EPZM) - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 8 at 8:44 AM
News IconPlacing Epizyme, Inc. (NASDAQ:EPZM) Shares Under the Microscope - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 8 at 8:44 AM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Other Events (NASDAQ:EPZM)
biz.yahoo.com - September 7 at 5:01 PM
finance.yahoo.com logo10:02 am Epizyme discloses IDMC has confirmed that the study cohort has surpassed its pre-specified futility hurdle; plans to present mature data in 1H17 (NASDAQ:EPZM)
finance.yahoo.com - September 7 at 5:01 PM
News IconStock Struggling for the Quarter: Epizyme, Inc. (NASDAQ:EPZM) - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 4 at 9:19 AM
News IconStock in Review: Taking a Closer Look at Epizyme, Inc. (NASDAQ:EPZM) Shares - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - September 1 at 7:22 AM
publicnow.com logoEpizyme to Present at Upcoming Investor Conferences (NASDAQ:EPZM)
www.publicnow.com - September 1 at 7:22 AM
fidaily.com logoEpizyme, Inc. (EPZM) Reaches 52-Week Low - Finance Daily (NASDAQ:EPZM)
www.fidaily.com - August 24 at 4:48 PM
News IconStock Tracking Lower for the Quarter: Epizyme, Inc. (NASDAQ:EPZM) - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - August 20 at 4:49 PM
News IconCrowd & Street Monitoring Epizyme, Inc. (NASDAQ:EPZM) - Post News (NASDAQ:EPZM)
www.kentuckypostnews.com - August 18 at 6:35 AM
realistinvestor.com logoAnalysts See Epizyme, Inc. (NASDAQ:EPZM) Reporting EPS Of $-0.66 - RealistInvestor.com (NASDAQ:EPZM)
www.realistinvestor.com - August 17 at 5:03 PM
finance.yahoo.com logoEPIZYME, INC. Financials (NASDAQ:EPZM)
finance.yahoo.com - August 16 at 4:57 PM
fidaily.com logoEpizyme, Inc. (EPZM) Position Down in Latest Report from Primecap Management Co/ca/ Last Quarter - Finance Daily (NASDAQ:EPZM)
www.fidaily.com - August 12 at 4:55 PM
fidaily.com logoEpizyme, Inc. (EPZM) Position Down in Latest Report from Primecap Management Co/ca/ Last Quarter (NASDAQ:EPZM)
www.fidaily.com - August 12 at 4:55 PM
streetinsider.com logoEpizyme (EPZM) Commences Dosing in Tazemetostat Phase 2 as Mesothelioma Treatment (NASDAQ:EPZM)
www.streetinsider.com - August 11 at 10:44 PM
capitalcube.com logoETF’s with exposure to Epizyme, Inc. : August 11, 2016 (NASDAQ:EPZM)
www.capitalcube.com - August 11 at 5:01 PM
finance.yahoo.com logoEpizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma (NASDAQ:EPZM)
finance.yahoo.com - August 11 at 6:58 AM
capitalcube.com logoEpizyme, Inc. :EPZM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:EPZM)
www.capitalcube.com - August 10 at 5:02 PM
marketexclusive.com logoIs The Epizyme Inc (NASDAQ:EPZM) Dip A Discount Entry Opportunity? (NASDAQ:EPZM)
marketexclusive.com - August 9 at 9:07 PM
marketexclusive.com logoIs The Epizyme Inc (NASDAQ:EPZM) Dip A Discount Entry Opportunity? - Market Exclusive (NASDAQ:EPZM)
marketexclusive.com - August 9 at 3:33 PM
4-traders.com logoEpizyme : reports 2Q loss (NASDAQ:EPZM)
www.4-traders.com - August 9 at 7:01 AM
finance.yahoo.com logoEdited Transcript of EPZM earnings conference call or presentation 8-Aug-16 12:30pm GMT (NASDAQ:EPZM)
finance.yahoo.com - August 8 at 10:11 PM
sg.finance.yahoo.com logoEpizyme reports 2Q loss (NASDAQ:EPZM)
sg.finance.yahoo.com - August 8 at 9:40 AM
publicnow.com logoEpizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives (NASDAQ:EPZM)
www.publicnow.com - August 8 at 9:40 AM
biz.yahoo.com logoQ2 2016 Epizyme Inc Earnings Release - Before Market Open (NASDAQ:EPZM)
biz.yahoo.com - August 8 at 9:40 AM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:EPZM)
biz.yahoo.com - August 8 at 9:40 AM
finance.yahoo.com logoEpizyme (EPZM) Posts Narrower-Than-Expected Loss in Q2 (NASDAQ:EPZM)
finance.yahoo.com - August 8 at 9:40 AM
biz.yahoo.com logoEPIZYME, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:EPZM)
biz.yahoo.com - August 8 at 9:40 AM


Epizyme (NASDAQ:EPZM) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by MarketBeat.com Staff